mTOR Inhibitor Compounds for Polycystic Kidney Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for polycystic kidney disease (PKD) and polycystic liver disease (PLD) lack effective FDA-approved therapeutic drugs, with existing clinical trials showing limited clinical effectiveness, necessitating the development of new compounds that can inhibit the mTOR signaling pathway, induce the unfolded protein response, and perturb mitochondrial function to address cyst cell growth and proliferation.
Innovation Solution
Development of compounds of Formula (I) or (II), which include specific chemical structures capable of inhibiting the mTOR signaling pathway, inducing the unfolded protein response, and perturbing mitochondrial function in cyst cells, formulated into pharmaceutical compositions for treating and preventing PKD and PLD, inhibiting cyst cell growth, and killing cyst cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (hemodialysis, peritoneal dialysis, renal transplantation, cyst aspiration, cyst fenestration, liver resection) are used for PKD and PLD, then patients can receive standard care, but these treatments do not directly target the underlying disease mechanism and have limited long-term effectiveness
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (mTOR signaling pathway) that drives cyst formation and growth in PKD and PLD. By developing compounds that specifically inhibit this pathway, the treatment directly addresses the root cause rather than managing symptoms, thereby improving reliability while maintaining a focused approach rather than increasing complexity
Solution Approach 2:
The patent changes the therapeutic parameter from mechanical intervention (surgery, dialysis) to molecular intervention (small molecule inhibitors). This parameter change enables direct targeting of the disease mechanism through chemical compounds that modulate cellular signaling, improving treatment effectiveness without requiring complex surgical or mechanical systems
2Reliability
If mTOR inhibitors (such as rapamycin) are used to treat PKD, then the mTOR pathway is inhibited, but these inhibitors have not shown significant clinical effectiveness
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features ( Formula I and Formula II structures with particular substituent patterns) that enable selective and potent inhibition of mTOR in cyst cells. This localized molecular design improves effectiveness at lower concentrations compared to non-selective inhibitors like rapamycin
Solution Approach 2:
The patent employs composite molecular structures combining specific pharmacophores and substituent groups (R1, R2, R3, R4, R5, R6, R7, R8 definitions in the patent) to create optimized mTOR inhibitors. This composite approach at the molecular level enhances potency and selectivity, achieving better clinical effectiveness with appropriate dosing
3Reliability
If compounds of Formula (I) or (II) are developed to inhibit mTOR signaling pathway, induce UPR, and perturb mitochondrial function, then cyst cell growth and proliferation can be targeted, but this requires developing new pharmaceutical compositions and formulations
Solution Approach 1:
The patent segments the therapeutic approach into distinct functional components: (1) mTOR pathway inhibition, (2) unfolded protein response induction, and (3) mitochondrial function perturbation. By designing compounds that address multiple targets simultaneously through their molecular structure, the patent improves therapeutic potential while the segmented approach to development helps manage formulation complexity systematically
Data Source
AI summary
The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.